Suzuken stock targets October 19 restart at Kumamoto plant

Published on 11/01/2026 at 00:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Suzuken stock faces a key supply update as its Sanwa Kagaku subsidiary prepares to restart Kumamoto production. The plant was damaged by a July earthquake.

Kumamoto restart supports supply planning

Suzuken said its Sanwa Kagaku Kenkyusho subsidiary would resume production at the Kumamoto plant on October 19 after earthquake damage.
The restart followed inspections, repairs and safety checks under Good Manufacturing Practice standards.
Suzuken plans to revise production schedules and coordinate with contract-manufacturing clients to stabilize deliveries.

Suzuken, JP3398000004, Illustration mit AI erstellt.

Suzuken said its pharmaceutical subsidiary Sanwa Kagaku Kenkyusho would resume production at its Kumamoto plant on October 19, following damage from the July 2026 earthquake. The Globe and Mail reported that inspections, repairs and safety checks under Good Manufacturing Practice standards had cleared the facility for a restart.

Production restart targets supply stability

The Kumamoto plant had been suspended after the earthquake. Suzuken said it would revise production schedules to normalize supply as quickly as possible and coordinate with contract-manufacturing clients to support stable deliveries.

The company also said it would maintain its focus on safety and quality at the facility and strengthen production systems. For investors, the restart addresses an operational disruption, while execution and the pace of supply normalization remain the next practical milestones.

Suzuken's healthcare operations

Suzuken is a Japan-based healthcare group listed on the Prime Market of the Tokyo Stock Exchange. Through subsidiaries including Sanwa Kagaku Kenkyusho, it manufactures pharmaceutical products and supplies contract-manufactured medicines to client companies. Its operations therefore combine healthcare manufacturing with related services for pharmaceutical customers.